A variant in TNFSF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was associated with both multiple sclerosis and SLE.
Fifteen different classes of transcripts detected 4 circulating exosomal sequences within the miRNA category that were differentially expressed.
Over a 5-year follow-up, there was no correlation between 24-hour urine sodium levels and conversion to clinically definite MS.
Communication with a pharmacist may help improve treatment adherence in multiple sclerosis.
The post-hoc analysis sought to identify factors predictive of relapse and disability progression in people with MS enrolled in the TRANSFORMS study.
Researchers sought to determine whether treatment with ocrelizumab improved measures of cognitive function better than interferon beta 1-a.
Initial trials of teriflunomide have demonstrated low lymphocyte counts in patients with relapsing forms of MS.
In patients with MS, hand function often correlates with measures of quality of life.
The prevalence of osteoporosis was greater in patients with MS than in matched controls.
Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.
Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.
Longer studies are needed to further evaluate the effect of vitamin D supplementation on cognition in multiple sclerosis.
Increased risk of pediatric multiple sclerosis was observed in patients with prior exposure to EBV, HSV-1, and vitamin D deficiency.
In older patients with relapsing multiple sclerosis, patient-reported fatigue and problems with lower extremities may signal conversion to secondary progressive disease.
More participants achieved clinical NEDA with DMF than placebo over 2 years in the integrated analysis.
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.
Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.
Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.
Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.
Previous MRI studies focused on gray matter changes only.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.
Neurology Advisor Articles
- Serum Cytokine Levels May Correlate With Cognitive Dysfunction in Alzheimer's Disease
- Migraine-Associated Stroke Not Linked to Atherosclerosis
- Ptosis Repair Effective for Reducing Tension-Type Headache
- Intracranial Hemorrhage Associated with Arteriovenous Malformations Linked to Better Outcomes
- MRI-Guided Focused Ultrasound More Cost Effective Treatment for Essential Tremor
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Stroke and Dementia Associated with Artificially-Sweetened Drinks?
- Case Report: DBS for the Treatment of Dystonia in Huntington's
- Treating Movement Disorders With Telemedicine: Getting Started
- Poor Quality of Sleep, Quality of Life in Patients With Lupus